Kane Biotech to Showcase Technologies and Products at the 2018 BIO International Convention
WINNIPEG, Manitoba, June 01, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will be attending the 2018 BIO International Convention being held June 4-7, 2018 at the Boston Convention Center in Boston, MA. Mark Ahrens-Townsend, President & Chief Executive Officer, Grant Humphrey, Vice President of Sales & Business Development, and two of Kane Biotech’s senior scientists – Karen LoVetri and Nanda Yakandawala will be attending the Convention and hosting Kane Biotech’s exhibit booth (Booth 1113), showcasing the Corporation’s technologies and products that break up bacterial biofilm in the human, animal, commercial, institutional and industrial sectors. Kane Biotech management will also participate in meetings with potential clinical and commercial partners, investors and other parties at their booth and in the Business Forum.
Kane Biotech’s booth is located on the floor of the Expo and will showcase numerous products and technologies of the Corporation including DispersinB®, Aledex®, Strix Oral Care, and Strix Wound Care technologies.
Kane Biotech has developed and commercialized bluestem™ and StrixNB™ oral care products for companion pets. Both contain a unique formulation scientifically developed to safely break down oral biofilms (plaque and tartar on teeth) and reduce halitosis. Bluestem™ and StrixNB™ are available in multiple products including a water additive, toothpaste, oral spray and a bulk powder in the pet specialty and veterinary channels, respectively.
DispersinB® is an antibiofilm enzyme which has been incorporated into several products including a DispersinB®-Gentamycin wound spray and a DispersinB® otic drop for the treatment of acute and chronic ear infections in dogs. Kane Biotech’s StrixNB™ and DispersinB® technologies are licensed to Dechra Veterinary Products LLC for distribution in the North American veterinary channel. Dechra markets the StrixNB™ technology under its Vetradent™ brand name.
Aledex® is a broad-spectrum, anti-microbial/antibiofilm medical device coating comprising two FDA-approved compounds, protamine sulfate and chlorhexidine (CHX). The technology has been shown to inhibit the activity of numerous catheter associated pathogens and protect against related infections.
Kane Biotech is also developing products incorporating its Strix Wound Care technology that will aid in treating the symptoms of inflammatory skin disorders in humans and animals such as atopic dermatitis, seborrheic dermatitis and athlete’s foot.
Kane Biotech’s mission is to discover and commercialize technologies that will prevent biofilm related infections in humans and animals as well as biofilm related problems in institutional, commercial and industrial applications. Biofilms are formed when bacteria adhere to surfaces and excrete a glue-like substance that acts as an anchor and provides protection from the environment. Biofilm formation can make bacteria up to 1000 times more resistant to antibiotics, antimicrobial agents, disinfectants and the host immune system and are acknowledged to be one of the main contributors to the “antibiotic resistance crisis”. Biofilms are estimated to be responsible for 80% of all human infections and cost industry, governments and hospitals in excess of $500 billion each year.
Investors, potential partners, and interested parties attending the conference who would like to meet with Kane Biotech management and scientists are encouraged to contact Kane Biotech Investor Relations at tpatel@edisongroup.com.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter.
The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Mark Ahrens-Townsend
President & CEO
Kane Biotech Inc.
+1 (204) 477-7592 ir@kanebiotech.com
Tirth Patel
Vice President - Investor Relations
Edison Advisors
+1 (646) 653-7035 tpatel@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
These risks and uncertainties should be considered carefully undue reliance should not be placed on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement.